Analyst Price Targets — VSTM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:31 am | — | RBC Capital | $14.00 | $4.46 | TheFly | Verastem price target lowered to $14 from $15 at RBC Capital |
| June 24, 2026 1:37 pm | Leonid Timashev | RBC Capital | $15.00 | $4.33 | StreetInsider | RBC Capital on Verastem (VSTM): 'We think shares are undervalued' |
| June 23, 2026 12:34 pm | — | Jefferies | $8.00 | $4.32 | TheFly | Verastem price target lowered to $8 from $15 at Jefferies |
| May 8, 2026 11:26 am | — | BTIG | $18.00 | $5.66 | TheFly | Verastem price target lowered to $18 from $19 at BTIG |
| May 8, 2026 11:04 am | — | Industrial Alliance Securities | $18.00 | $5.66 | TheFly | Verastem price target raised to $18 from $16 at Alliance Global |
| March 5, 2026 3:06 pm | Clara Dong | Jefferies | $19.00 | $6.18 | StreetInsider | Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026" |
| February 19, 2026 12:18 pm | — | Mizuho Securities | $18.00 | $5.71 | TheFly | Verastem price target raised to $18 from $15 at Mizuho |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $15.00 | $8.85 | TheFly | Verastem price target raised to $15 from $14 at Mizuho |
| October 21, 2025 2:08 pm | Graig Suvannavejh | Mizuho Securities | $14.00 | $8.12 | StreetInsider | Mizuho Reiterates Outperform Rating on Verastem (VSTM) |
| October 21, 2025 10:48 am | Swayampakula Ramakanth | H.C. Wainwright | $14.00 | $8.02 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM) |
Latest News for VSTM
Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant…
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.
Verastem, Inc. is maintained at a Buy rating, driven by upcoming clinical catalysts and positive early-stage data in KRAS G12D mutant solid tumors. VSTM expects key data readouts from the TARGET-D 101 phase 1/2 study in 2026 and is advancing three phase 2 registration-directed studies for PDAC, NSCLC, and CRC for VS-7375. Positive phase 1b/2a RAMP 205 results in 1st-line metastatic PDAC (86% OS at 6 months, 52%…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VSTM.
U.S. House Trading
No House trades found for VSTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.